samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CrystecPharma win CPhI Excellence in Pharma Award for Contract Services and Outsourcing

Crystec are delighted to have been awarded the CPhI Excellence in Pharma Award for Contract Services and Outsourcing

The award was presented for Crystec’s modified supercritical anti-solvent (mSAS) technology for accelerated product development, and chosen from shortlisted companies including 3M, Alcami, Catalent Pharma Services and Merck.

The winners of the CPhI Awards were announced on Tuesday 24th October during an awards gala in Frankfurt, Germany. Crystec’s CEO, Paul Thorning, said of the prestigious award: “It is our great pleasure to have been recognised for our work across the industry through our expertise in crystallisation and particle engineering. Our mSAS technology platform has the potential, not only to add value to product development programmes through improving the performance of medicines, but to streamline product development, reduce manufacturing costs and accelerate the route to market. We are very proud of our company and of the solutions that we provide for our clients, as well as our own development programmes. We are particularly honoured to have won this award in the company of such renowned organisations.”

For more information about Crystec’s mSAS technology, please contact Emily Bevis (emily.bevis@crystecpharma.com).

About CPhI
The International Convention on Pharmaceutical Ingredients and Intermediates (CPhI) hold several events each year aimed at bringing together people from across the pharmaceutical supply chain. CPhI Worldwide is the largest and most diverse gathering of pharmaceutical professionals in the world. With over 42,000 visiting professionals and more than 2500 exhibitors from 153 countries, there is no better platform to explore new business opportunities.

About CPhI Awards
Established in 2004, the CPhI Pharma Awards are among the most prestigious recognitions within the Pharmaceutical industry. The Awards celebrates thinkers and creators breaking new ground and strongly advocates companies committed to driving the industry forward.


About Crystec
CrystecPharma is a pharmaceutical crystal and particle engineering company, applying supercritical fluid technology to improve the performance of medicines. The company has a strong research and development base, in both the UK and China. Crystec supports pharmaceutical companies to optimise the development of their own products, typically through improving bioavailability, stability or changing routes of administration. The company also applies the strength of its technology to develop its own supergeneric products. Crystec is a young, dynamic company, with a passion for ensuring that strong science benefits human health. For more information, please visit www.crystecpharma.com.

Crystec Ltd.
Norcroft Building
Richmond Road
Bradford, United Kingdom
BD7 1DP

T: +44 1274 235592
E: info@crystecpharma.com
 
Print this page
Send to a friend
   
spacer
News and Press Releases

CPhI Worldwide: TE-ring remains firmly attached to the dropper bottle in line with FDA requirements

Düsseldorf/Frankfurt, October 24, 2017 – It is often only minor improvements that make a product ideal to use. The TE-ring fixed to the type A eye-dropper bottle in accordance with the new FDA regulations is one good example.
More info >>


White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement